Summary
EudraCT Number: 2005-001372-12
Sponsor's Protocol Code Number: 1100.1426
National Competent Authority: UK - MHRA 
Clinical Trial Type: EEA CTA
Trial Status: Completed
Date on which this record was first entered in the EudraCT database: 2005-07-15
Link: https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-001372-12/GB/

A. Protocol Information
A.1 Member State Concerned: UK - MHRA
A.2 EudraCT number: 2005-001372-12
A.3 Full title of the trial: An open-label, non-randomized, single arm study, to investigate the mechanism(s) by which nevirapine increases plasma high density lipoproteins concentration in HIV + subjects treated with Viramune tablets
A.3.2 Name or abbreviated title of the trial where available: NILE study
A.4.1 Sponsor's protocol code number: 1100.1426
A.7 Trial is part of a Paediatric Investigation Plan: Information not present in EudraCT
A.8 EMA Decision number of Paediatric Investigation Plan: 

B. Sponsor Information
Sponsor 1
B.1.1 Name of Sponsor: Boehringer Ingelheim Netherlands B.V.
B.1.3.4	Country: Netherlands
B.3.1 and B.3.2	Status of the sponsor: Commercial
B.4 Source(s) of Monetary or Material Support for the clinical trial:
B.4.1 Name of organisation providing support:
B.4.2 Country:
B.5 Contact point designated by the sponsor for further information on the trial
B.5.1 Name of organisation: 
B.5.2 Functional name of contact point: 

D. IMP Identification
D.IMP: 1
D.1.2 and D.1.3 IMP Role: Test
D.2 Status of the IMP to be used in the clinical trial
D.2.1 IMP to be used in the trial has a marketing authorisation: Information not present in EudraCT
D.2.1.1.1 Trade name: Viramune 200 mg tablets
D.2.1.1.2 Name of the Marketing Authorisation holder: Boehringer Ingelheim International GmbH
D.2.1.2 Country which granted the Marketing Authorisation: United Kingdom
D.2.5 The IMP has been designated in this indication as an orphan drug in the Community: No
D.2.5.1 Orphan drug designation number: 
D.3 Description of the IMP
D.3.1 Product name: Viramune 200 mg Tablets
D.3.4 Pharmaceutical form: Tablet
D.3.4.1 Specific paediatric formulation: Information not present in EudraCT
D.3.7 Routes of administration for this IMP:
Oral use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8 INN - Proposed INN: Nevirapine anhydrous
D.3.9.2 Current sponsor code: BIRG-587
D.3.10 Strength
D.3.10.1 Concentration unit: mg/g milligram(s)/gram
D.3.10.2 Concentration type: equal
D.3.10.3 Concentration number: 200 
D.3.11 The IMP contains an
D.3.11.1 Active substance of chemical origin: Yes
D.3.11.2 Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP): No
D.3.11.3 Advanced Therapy IMP (ATIMP): Information not present in EudraCT
D.3.11.3.1 Somatic cell therapy medicinal product: No
D.3.11.3.2 Gene therapy medical product: No
D.3.11.3.3 Tissue Engineered Product: Information not present in EudraCT
D.3.11.3.4 Combination ATIMP (i.e. one involving a medical device): Information not present in EudraCT
D.3.11.3.5 Committee on Advanced therapies (CAT) has issued a classification for this product: Information not present in EudraCT
D.3.11.4 Combination product that includes a device, but does not involve an Advanced Therapy: Information not present in EudraCT
D.3.11.5 Radiopharmaceutical medicinal product: No
D.3.11.6 Immunological medicinal product (such as vaccine, allergen, immune serum): No
D.3.11.7 Plasma derived medicinal product: Information not present in EudraCT
D.3.11.8 Extractive medicinal product: Information not present in EudraCT
D.3.11.9 Recombinant medicinal product: Information not present in EudraCT
D.3.11.10 Medicinal product containing genetically modified organisms: No
D.3.11.11 Herbal medicinal product: No
D.3.11.12 Homeopathic medicinal product: No
D.3.11.13 Another type of medicinal product: No

D.8 Information on Placebo

E. General Information on the Trial
E.1 Medical condition or disease under investigation
E.1.1 Medical condition(s) being investigated: Treatment of HIV infection
MedDRA Classification
E.1.3 Condition being studied is a rare disease: No
E.2 Objective of the trial
E.2.1 Main objective of the trial: To investigate the mechanism(s) by which Nevirapine increases plasma HDL concentration.

To evaluate the effect of increased HDL on endothelial function as a surrogate endpoint for cardiovascular disease.
E.2.2 Secondary objectives of the trial: The percentage change  of fractional synthethic rate (FSR) of APO A-1 from week 0 (baseline) to 24 weeks of treatment with NVP-based antiretroviral therapy.

The percentage change in plasma levels of lipoproteins in the fasting lipid panel from week 0 (baseline) to 6 weeks and at 24 weeks of treatment with NVP-based antiretroviral therapy.

The percent change in activity (and/or mass) of the constituents of the lipid enzymes panel at 6 and 24 weeks of NVP-based antiretroviral therapy.
E.2.3 Trial contains a sub-study: Information not present in EudraCT
E.3 Principal inclusion criteria: 18 years of age or older
Patients on stable therapy with Trizivir only (or its equivalent component drugs), for at least 6 months prior to screening
Patients with HIV-1-RNA< or equal 50 copies/ml documented on at least two occasions within 6 months prior to enrollment
Documentation of plasma HIV-1-RNA< or equal 50 copies/ml for> or equal 6 months while on Trizivir without other ARV. 
Ability and willingness to complete the study
E.4 Principal exclusion criteria: Previous exposure to NNRTI drugs
documented diabetes mellitus
Hypertension
fasting hypertriglyceridemia (>5.6 mmol/L or 500 mg/dl)
use of lipid-lowering medication during the 90 days prior study enrollment
chronic active hepatitis B and/or C
Anemia
active opportunistic infection or neoplasm within 3 months prior to screening
Any history of CV disease
Hepatic, renal or thyroid abnormalities
Pregnancy or lactation
Active anticoagulation therapy
History of HIV-2 infection
Active alcohol/drug abuse
ALT/AST > 2.5 x ULN
Total Bilirubin > 2 x ULN
Use of anabolic steroids during the 90 days prior to study enrollment
Patients on any therapy for which a stable regimen has not been achieved for at least 28 days prior to visit 2
Female patients with CD4 counts >250 cells/mm3
Male patients with CD 4 counts >400 cells/mm3
Patients taking and unable to discontinue any of the restricted drugs:
- Any investigational agent
- All lipid regulating agents (e.g. high dose niacin, fibrates, bile acid sequestering resins, HMG-CoA reductase inhibitors, psyllium derivatives or fish oil)
- Azole antifungal agents (IV/oral)
- Macrolides
- Rifampicin, rifabutin
- St. Johns Wort
- Antihypertensive medication with known effects on the vascular endothelium (e.g. calcium channel blockers, ACE inhibitors)
E.5 End points
E.5.1 Primary end point(s): The percentage change of fractional synthetic rate (FSR) of apo A-I from week 0 (baseline) to 6 weeks of treatment with NVP-based antiretroviral therapy.

The percentage change of flow mediated dilatation (FMD) from week 0 (baseline) to 6 and 24 weeks of treatment with NVP-based antiretroviral therapy.
E.6 and E.7 Scope of the trial
E.6 Scope of the Trial
E.6.1 Diagnosis: Information not present in EudraCT
E.6.2 Prophylaxis: Information not present in EudraCT
E.6.3 Therapy: Information not present in EudraCT
E.6.4 Safety: Yes
E.6.5 Efficacy: Information not present in EudraCT
E.6.6 Pharmacokinetic: Yes
E.6.7 Pharmacodynamic: Yes
E.6.8 Bioequivalence: Information not present in EudraCT
E.6.9 Dose response: Information not present in EudraCT
E.6.10 Pharmacogenetic: Information not present in EudraCT
E.6.11 Pharmacogenomic: Information not present in EudraCT
E.6.12 Pharmacoeconomic: Information not present in EudraCT
E.6.13 Others: Information not present in EudraCT
E.7 Trial type and phase 
E.7.1 Human pharmacology (Phase I): Information not present in EudraCT
E.7.1.1 First administration to humans: Information not present in EudraCT
E.7.1.2 Bioequivalence study: Information not present in EudraCT
E.7.1.3 Other: Information not present in EudraCT
E.7.1.3.1 Other trial type description: 
E.7.2 Therapeutic exploratory (Phase II): Information not present in EudraCT
E.7.3 Therapeutic confirmatory (Phase III): Information not present in EudraCT
E.7.4 Therapeutic use (Phase IV): Yes
E.8 Design of the trial
E.8.1 Controlled: No
E.8.1.1 Randomised: No
E.8.1.2 Open: Yes
E.8.1.3 Single blind: No
E.8.1.4 Double blind: No
E.8.1.5 Parallel group: No
E.8.1.6 Cross over: No
E.8.1.7 Other: Information not present in EudraCT
E.8.2 Comparator of controlled trial
E.8.2.1 Other medicinal product(s): No
E.8.2.2 Placebo: No
E.8.2.3 Other: No
E.8.3 The trial involves single site in the Member State concerned: No
E.8.4 The trial involves multiple sites in the Member State concerned: Yes
E.8.5 The trial involves multiple Member States: Yes
E.8.6 Trial involving sites outside the EEA
E.8.6.1 Trial being conducted both within and outside the EEA: No
E.8.6.2 Trial being conducted completely outside of the EEA: Information not present in EudraCT
E.8.7 Trial has a data monitoring committee: Information not present in EudraCT
E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial: as defined in the protocol
E.8.9 Initial estimate of the duration of the trial
E.8.9.1 In the Member State concerned years: 1
E.8.9.1 In the Member State concerned months: 3
E.8.9.1 In the Member State concerned days: 
E.8.9.2 In all countries concerned by the trial years: 2
E.8.9.2 In all countries concerned by the trial months: 9

F. Population of Trial Subjects
F.1 Age Range
F.1.1 Trial has subjects under 18: No
F.1.1.1 In Utero: Information not present in EudraCT
F.1.1.2 Preterm newborn infants (up to gestational age < 37 weeks): Information not present in EudraCT
F.1.1.3 Newborns (0-27 days): Information not present in EudraCT
F.1.1.4 Infants and toddlers (28 days-23 months): Information not present in EudraCT
F.1.1.5 Children (2-11years): Information not present in EudraCT
F.1.1.6 Adolescents (12-17 years): Information not present in EudraCT
F.1.2 Adults (18-64 years): Yes
F.1.3 Elderly (>=65 years): Yes
F.2 Gender
F.2.1 Female: Yes
F.2.2 Male: Yes
F.3 Group of trial subjects
F.3.1 Healthy volunteers: No
F.3.2 Patients: Yes
F.3.3 Specific vulnerable populations: Information not present in EudraCT
F.3.3.1 Women of childbearing potential not using contraception  
(For clinical trials recorded in the database before the 10th March 2011 this question read: "Women of childbearing potential" and
did not include the words "not using contraception". An answer of yes could have included women of child bearing potential whether
or not they would be using contraception. The answer should therefore be understood in that context. This trial was recorded in the
database on 2005-07-15) : Yes
F.3.3.2 Women of child-bearing potential using contraception: Information not present in EudraCT
F.3.3.3 Pregnant women: No
F.3.3.4 Nursing women: No
F.3.3.5 Emergency situation: No
F.3.3.6 Subjects incapable of giving consent personally: No
F.3.3.6.1 Details of subjects incapable of giving consent: women of childbearing potential who are able/willing to use effective method of barrier contraception
F.3.3.7 Others: No
F.4 Planned number of subjects to be included
F.4.1 In the member state: 10
F.4.2 For a multinational trial
F.4.2.1 In the EEA: 20
F.4.2.2 In the whole clinical trial: 20

G. Investigator Networks to be involved in the Trial


N. Review by the Competent Authority or Ethics Committee in the country concerned
N. Competent Authority Decision: Authorised
N. Date of Competent Authority Decision: 2005-08-15
N. Ethics Committee Opinion of the trial application: Favourable
N. Ethics Committee Opinion: Reason(s) for unfavourable opinion:
N. Date of Ethics Committee Opinion: 2005-11-30

P. End of Trial
P. End of Trial Status: Completed
P. Date of the global end of the trial: 2007-11-23

